Guatemala is a promoted option for first-in-human sponsors who need a larger national population than Panama, El Salvador, or Costa Rica, positioned alongside the Dominican Republic. The World Bank estimates about 18.7 million people in Guatemala and about 11.5 million in the Dominican Republic for 2025. MSPAS, through DRCPFA, authorizes trials under Ministerial Agreement 206-2021 after an authorized ethics committee approves the study, and section 47 allows up to 30 business days after a complete file. That is not an ethics-committee clock or a startup promise. Population is not an enrollment forecast. There is no published bioaccess® Guatemala enrollment figure, and this site cites no completed Guatemala trials, sites, investigators, or patient numbers. Ask for a protocol-specific feasibility assessment.
| Metric | bioaccess® | Guatemala |
|---|---|---|
| Role in your plan | One First-in-Human CRO that plans the protocol across jurisdictions and assesses Guatemala as an option for it | One national pathway: MSPAS through DRCPFA, under Ministerial Agreement 206-2021 |
| Population (World Bank, 2025) | Dominican Republic about 11.5 million; El Salvador about 6.4 million; Costa Rica about 5.2 million; Panama about 4.6 million (World Bank, 2025) | About 18.7 million, or about 1.6 times the Dominican Republic by our calculation. INE Guatemala’s own mid-2025 projection is lower, about 18.1 million |
| Ethics step | Ethics review timed to each committee’s meeting schedule; we confirm it per protocol | An authorized ethics committee approves before the file goes to DRCPFA (sections 37.8 and 42). Each committee sets its own meeting frequency and maximum response time (section 38.7) |
| Authority clock | Study-specific; confirmed per protocol | Up to 30 business days after DRCPFA receives complete documentation, 15 business days to answer a query, and 15 business days for the final decision (section 47). Not an ethics clock or a startup promise |
| Language of the file | Translations planned per country in the protocol-specific regulatory plan | Protocol written in Spanish (section 42.11); investigator brochure may be in its original language with a Spanish summary (section 42.12) |
| Per-patient / program cost | Budget depends on study design; we provide a study-specific quote. | There is no published Guatemala cost or savings figure on this site; budget follows the protocol |
| FDA acceptance & data applicability | Data conducted under GCP (ISO 14155 for devices; ICH E6 for drugs) is eligible for FDA submission and review under 21 CFR 812.28 or 312.120. Eligibility is not clearance or approval | Our Guatemala page states the same conditional 21 CFR 812.28 eligibility, including ethics-committee oversight and informed consent |
| Track record in the country | Verified programs are listed in the trial evidence registry | There is no published bioaccess® Guatemala enrollment figure, and this site cites no completed Guatemala trials, sites, investigators, or patient numbers |
Comparison uses widely-known category facts about Guatemala and published US benchmark ranges — not Guatemala-specific figures. bioaccess® figures reflect our FIH-12™ operating model.
Guatemala is worth weighing when population scale matters. The World Bank estimates about 18.7 million people for 2025, about 1.6 times the Dominican Republic, and more than Panama, El Salvador, and Costa Rica combined (about 16.1 million). A larger national population is not an enrollment forecast: recruitment depends on the indication, the protocol, the investigator, and the site.
The pathway is published. MSPAS, through DRCPFA, authorizes trials under Ministerial Agreement 206-2021, with an authorized ethics committee approving the study first. Section 47 sets up to 30 business days after complete documentation. That is a statutory period, not an ethics-committee clock and not a startup promise. Our Guatemala page walks through the sequence.
bioaccess® is the same First-in-Human CRO on that file as on the others: Miami headquarters, U.S. regulatory anchoring, and a protocol-specific plan. We make capability and approach statements about Guatemala, not claims of completed work. Foreign data is eligible for FDA submission and review under 21 CFR 812.28 when GCP / ISO 14155, ethics, and consent are met. Eligibility is not clearance or approval.
No. Our Guatemala page, /clinical-trials-guatemala, covers the MSPAS / DRCPFA pathway, the ethics step, the dossier, import, and insurance in detail. This comparison weighs Guatemala as a destination beside a bioaccess® plan.
The World Bank estimates 18,687,881 people in Guatemala and 11,520,487 in the Dominican Republic for 2025 (World Development Indicators, SP.POP.TOTL), about 1.6 times as many by our calculation. INE Guatemala projects 18,079,810 for mid-2025, and the Dominican Republic’s 2022 census (ONE) counted 10,773,983. Population is not an enrollment forecast.
Section 47 of Ministerial Agreement 206-2021 allows up to 30 business days after DRCPFA receives complete documentation. A query gives the applicant 15 business days to respond, and the final decision follows within 15 business days of the new information. That is not an ethics-committee clock or a startup promise.
This site does not say that. It cites no completed Guatemala trials, sites, investigators, or patient numbers, and there is no published bioaccess® Guatemala enrollment figure. Ask for a protocol-specific feasibility assessment.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call